Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
7 stories
The company also disclosed a CFO transition, a debt repurchase, and a $24 million CYFENDUS contract modification as it narrows its full-year outlook.
SEC filing (23)
The company sold 16,428,572 shares at a $17.50 public offering price after underwriters fully exercised their option to buy additional stock.
SEC filing
Arcus proposed a common stock offering through underwriters Jefferies, Leerink Partners and TD Cowen, pointing to casdatifan results and an estimated $694.0 million cash balance.
SEC filing (3)
The company estimated about $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026, pending completion of its financial closing process.
SEC filing